Neuland Laboratories liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
16.47×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.09×2.09×2.45×2.15×1.73×
1.37×1.37×1.62×1.33×1.10×
76.776.724087.645.4
773773674493322
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NEULANDLAB₹18,695.00

Neuland Laboratories Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABLAURUSLABSNHNATCOPHARMLALPATHLABSAILIFECOHANCEASTERDMMcap ₹24,117 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Altman Z-Score (Other Equity as RE)————16.47
Current Ratio1.732.152.452.092.09
Quick Ratio1.101.331.621.371.37
Cash, Equiv & ST Investments45.487.6239.676.776.7
Working Capital321.9493.4673.8772.9772.9
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.